Grant number: 1019833 | Funding period: 2012 - 2016
Trials of numerous agents to slow the progression of Parkinsons disease have provided ambiguous or negative results despite having good preliminary evidence for their efficacy. The most likely reason is that many nerve cells are already destroyed by the time of diagnosis. Thus effective therapies may be most (and possible only) effective when administered in the presymptomatic stages of disease. This proposal is directed at developing method to detect early presymptomatic Parkinsons disease.
Related publications (13)
Galactose-functionalised PCL nanofibre scaffolds to attenuate inflammatory action of astrocytes in vitro and in vivo
Francesca L Maclean, Chew L Lau, Sam Ozergun, Ross D O'Shea, Cecilia Cederfur, Jason Wang, Kevin E Healy, Frederick R Walker, Doris Tomas, Malcolm K Horne, Philip M Beart, David R Nisbet
Astrocytes represent an attractive therapeutic target for the treatment of traumatic brain injury in the glial scar, which inhibit..
Walking the tightrope: proteostasis and neurodegenerative disease
Justin J Yerbury, Lezanne Ooi, Andrew Dillin, Darren N Saunders, Danny M Hatters, Philip M Beart, Neil R Cashman, Mark R Wilson, Heath Ecroyd
A characteristic of many neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's di..
Comparative Microarray Analysis Identifies Commonalities in Neuronal Injury: Evidence for Oxidative Stress, Dysfunction of Calcium Signalling, and Inhibition of Autophagy-Lysosomal Pathway
Yann Wan Yap, Roxana M Llanos, Sharon La Fontaine, Michael A Cater, Philip M Beart, Nam Sang Cheung
Mitochondrial dysfunction, ubiquitin-proteasomal system impairment and excitotoxicity occur during the injury and death of neurons..
Modulating Astrocyte Transition after Stroke to Promote Brain Rescue and Functional Recovery: Emerging Targets Include Rho Kinase
Hima Charika S Abeysinghe, Ellie L Phillips, Heung Chin-Cheng, Philip M Beart, Carli L Roulston
Stroke is a common and serious condition, with few therapies. Whilst previous focus has been directed towards biochemical events w..
Silent information regulator 1 modulator resveratrol increases brain lactate production and inhibits mitochondrial metabolism, whereas SRT1720 increases oxidative metabolism
Benjamin D Rowlands, Chew Ling Lau, James G Ryall, Donald S Thomas, Matthias Klugmann, Philip M Beart, Caroline D Rae
Silent information regulators (SIRTs) have been shown to deacetylate a range of metabolic enzymes, including those in glycolysis a..
Transcriptomic analysis and 3D bioengineering of astrocytes indicate ROCK inhibition produces cytotrophic astrogliosis
Ross D O'Shea, Chew L Lau, Natasha Zulaziz, Francesca L Maclean, David R Nisbet, Malcolm K Home, Philip M Beart
Astrocytes provide trophic, structural and metabolic support to neurons, and are considered genuine targets in regenerative neurob..
3D Electrospun scaffolds promote a cytotrophic phenotype of cultured primary astrocytes
Chew L Lau, Michelle Kovacevic, Tine S Tingleff, John S Forsythe, Holly S Cate, Daniel Merlo, Cecilia Cederfur, Francesca L Maclean, Clare L Parish, Malcolm K Horne, David R Nisbet, Philip M Beart
Astrocytes are a target for regenerative neurobiology because in brain injury their phenotype arbitrates brain integrity, neuronal..